IDXX - IDEXX Laboratories, Inc.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will b.
On May 11, 2026, IDEXX Laboratories Inc (IDXX) shares fell 5.0% to a current price of $532.00. This decline comes amid a challenging performance period for the
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
IDXX rides strong on Q1 beats with rising margins; lifts 2026 outlook as diagnostics growth and innovation momentum fuel performance.
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories Inc (NASDAQ:IDXX) shares are up on Tuesday as the company recently announced strong first-quarter results, showcasing a 14% revenue growth.
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter earnings per diluted share (“EPS”) were $3.47, an increase of 17% as reported and 15% on a c.
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
IDXX heads into Q1 earnings with strong growth forecasts, steady estimate beats, and momentum in diagnostics and recurring revenue streams.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Comerica Bank lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,493 shares of the company's stock after selling 9,639 shares during the quarter. Comerica Bank's holdings in IDEXX Laboratories
On April 29, 2026, we take a closer look at the DCF analysis for IDEXX Laboratories Inc (IDXX). The company has experienced a price performance of -0.1% over th
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYK heads into Q1 earnings with strong procedure demand and robotic surgery growth, but tariff and cost pressures may test margins.
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors. A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors.
AEGON ASSET MANAGEMENT UK Plc reduced its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 4.6% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,068 shares of the company's stock after selling 1,247 shares during the quarter. AEGON ASSET MANAGEMENT UK